Abstract
In late November 2021, the World Health Organization declared the SARS-CoV-2 lineage B.1.1.529 the fifth variant of concern, Omicron. This variant has acquired over 30 mutations in the spike protein (with 15 in the receptor-binding domain), raising concerns that Omicron could evade naturally acquired and vaccine-derived immunity. We utilized an authentic virus, multicycle neutralisation assay to demonstrate that sera collected one, three, and six months post-two doses of Pfizer-BioNTech BNT162b2 had a limited ability to neutralise SARS-CoV-2. However, four weeks after a third dose, neutralising antibody titres were boosted. Despite this increase, neutralising antibody titres were reduced fourfold for Omicron compared to lineage A.2.2 SARS-CoV-2.
Funder
NSW Ministry of Health
NSW Health
National Health and Medical Research Council
Institute of Clinical Pathology and Medical Research Trust Fund
Subject
Virology,Infectious Diseases
Reference32 articles.
1. Network for Genomic Surveillance in South Africa (NGS-SA) SARS-CoV-2 Sequencing Update 1 December 2021. Network for Genomic Surveillance in South Africa (NGS-SA)
https://www.nicd.ac.za/wp-content/uploads/2021/12/update-of-sa-sequencing-data-from-gisaid-1-dec-final.pdf
2. World Health Organization Statement—Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern 26 November 2021
3. The World Health Organization—Tracking SARS-CoV-2 Variants
4. The World Health Organization—COVID-19 Vaccines with WHO Emergency Use Listing
5. Neutralizing Activity of BNT162b2-Elicited Serum
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献